Reply to: Blood-Brain Barrier Heterogeneity in NRG BN007: Implications for Immunotherapy Delivery

Andrew B Lassman¹, Mei-Yin C Polley¹, Fabio M Iwamoto¹+4

• ¹Andrew B. Lassman, MD, MS, Division of Neuro-Oncology, Department of Neurology, Columbia University Vagelos College of Physicians and Surgeons, New York, NY, Herbert Irving Comprehensive Cancer Center, New York, NY, NewYork-Presbyterian, New York, NY, Mei-Yin C. Polley, PhD, NRG Oncology Statistics and Data Management Center, Chicago, IL, Department of Public Health Sciences, University of Chicago, Chicago, IL, Fabio M. Iwamoto, MD, Division of Neuro-Oncology, Department of Neurology, Columbia University Vagelos College of Physicians and Surgeons, New York, NY, Herbert Irving Comprehensive Cancer Center, New York, NY, NewYork-Presbyterian, New York, NY, Vinai Gondi, MD, Department of Radiation Oncology, Northwestern Medicine Cancer Center Warrenville and Proton Center, Warrenville, IL, Erik P. Sulman, MD, PhD, Department of Radiation Oncology, Duke University School of Medicine, Durham, NC, Duke Cancer Institute, Durham, NC, Jedd D. Wolchok, MD, PhD, Meyer Cancer Center and Department of Medicine, Weill Cornell Medicine, New York, NY, NewYork-Presbyterian, New York, NY, Minesh P. Mehta, MD, Department of Oncological Sciences, Florida International University, and Miami Cancer Institute, Baptist Health South Florida, Miami, FL.